Industrifonden research finds investors misjudge rare-disease deal timing and launch performance

• Industrifonden-backed research found investors misprice rare-disease deals, citing systematic gaps versus published benchmarks across 43 VC, pharma BD professionals.
• Survey results showed 84% underestimated rare-disease launch performance despite evidence most launches meet or beat analyst expectations.
• Only 9% correctly identified the most common acquisition exit point, suggesting prevalent-disease deal patterns skew rare-disease valuation assumptions.
• Greater industry experience increased willingness to estimate outcomes, without improving accuracy.
• Study warned miscalibration can distort risk pricing, capital allocation, deal timing across rare-disease assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Industrifonden published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.